» Articles » PMID: 28521777

CIP2A Mediates Fibronectin-induced Bladder Cancer Cell Proliferation by Stabilizing β-catenin

Overview
Publisher Biomed Central
Specialty Oncology
Date 2017 May 20
PMID 28521777
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Fibronectin (FN) is associated with tumorigenesis and progression in bladder cancer, however, the underlying mechanisms causing this remain largely unknown. Furthermore, cancerous inhibitor of protein phosphatase 2A (CIP2A) has been shown to play important regulatory roles in cancer proliferation. Here, we investigated whether FN regulates CIP2A expression to promote bladder cancer cell proliferation.

Methods: The correlations of stromal FN with CIP2A and proliferating cell nuclear antigen (PCNA) expression were analyzed in a cohort bladder cancer patients. The roles of FN and CIP2A in regulating bladder cancer cell proliferation were evaluated in cell and animal models. Cycloheximide treatment was used to determine the effects of CIP2A on β-catenin stabilization. The CIP2A-β-catenin interaction was confirmed by immunofluorescence staining and co-immunoprcipitation.

Results: In this study, we found that stromal FN expression correlated positively with the levels of CIP2A and PCNA in bladder cancer tissues. Meanwhile, in human bladder cancer cell lines (T24 and J82), exogenous FN significantly promoted cell proliferation, however, CIP2A depletion inhibited this process. Furthermore, the interaction between CIP2A and β-catenin enhanced the stabilization of β-catenin, which was involved in FN-induced cell proliferation. In vivo, CIP2A depletion repressed FN-accelerated subcutaneous xenograft growth rates.

Conclusions: These data reveal that CIP2A is a crucial mediator of FN-induced bladder cancer cell proliferation via enhancing the stabilization of β-catenin. Promisingly, FN and CIP2A could serve as potential therapeutic targets for bladder cancer treatment.

Citing Articles

CIP2A promotes bronchiolitis obliterans by activating the NF‑κB pathway.

Zhou X, Zhao X, Li Y, Zhang B Mol Med Rep. 2025; 31(4).

PMID: 40017141 PMC: 11881678. DOI: 10.3892/mmr.2025.13473.


Predicting bladder cancer survival with high accuracy: insights from MAPK pathway-related genes.

Cheng G, Zhou Z, Li S, Yang S, Wang Y, Ye Z Sci Rep. 2024; 14(1):10482.

PMID: 38714855 PMC: 11076554. DOI: 10.1038/s41598-024-61302-0.


CISD2 transcriptional activated by transcription factor E2F7 promotes the malignant progression of cervical cancer.

Wang L, Wang Y, Wang C, Yang K, Ye G J Mol Histol. 2023; 54(5):489-498.

PMID: 37615745 DOI: 10.1007/s10735-023-10145-6.


Sig1R activates extracellular matrix-induced bladder cancer cell proliferation and angiogenesis by combing β-integrin.

Zhao F, Yang T, Zhou L, Li R, Liu J, Zhao J Aging (Albany NY). 2023; 15(10):4182-4201.

PMID: 37199665 PMC: 10258007. DOI: 10.18632/aging.204721.


YWHAB knockdown inhibits cell proliferation whilst promoting cell cycle arrest and apoptosis in colon cancer cells through PIK3R2.

Zhou X, Chen A, Zhang T Exp Ther Med. 2023; 25(5):193.

PMID: 37090079 PMC: 10119628. DOI: 10.3892/etm.2023.11892.


References
1.
Gao H, Sun B, Fu H, Chi X, Wang F, Qi X . PDIA6 promotes the proliferation of HeLa cells through activating the Wnt/β-catenin signaling pathway. Oncotarget. 2016; 7(33):53289-53298. PMC: 5288186. DOI: 10.18632/oncotarget.10795. View

2.
Kamoshida G, Matsuda A, Miura R, Takashima Y, Katsura A, Tsuji T . Potentiation of tumor cell invasion by co-culture with monocytes accompanying enhanced production of matrix metalloproteinase and fibronectin. Clin Exp Metastasis. 2012; 30(3):289-97. DOI: 10.1007/s10585-012-9536-7. View

3.
Laine A, Sihto H, Come C, Rosenfeldt M, Zwolinska A, Niemela M . Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov. 2013; 3(2):182-97. PMC: 3572190. DOI: 10.1158/2159-8290.CD-12-0292. View

4.
Yang X, Huang H, Zeng Z, Zhao L, Hu P, He D . Diagnostic value of bladder tumor fibronectin in patients with bladder tumor: a systematic review with meta-analysis. Clin Biochem. 2013; 46(15):1377-82. DOI: 10.1016/j.clinbiochem.2013.05.064. View

5.
Ploussard G, Shariat S, Dragomir A, Kluth L, Xylinas E, Masson-Lecomte A . Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time. Eur Urol. 2013; 66(2):361-70. DOI: 10.1016/j.eururo.2013.09.050. View